Dana-Farber Cancer Institute

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Dana-Farber Cancer Institute

https://www.dana-farber.org/

LYNKED IN Patient Conference 2024
Multiple Myeloma Patient Symposium
2023-2024 EMBRACE MBC Virtual Forum Series
ASCO® GU 2024
ASCO® 2023
COVID-19
Leukemia
Lymphoma
Myeloma
MDS and MPN
Breast
Lung
Gynecologic
Genitourinary
Gastrointestinal
Colorectal
Basic Science
Supportive and Palliative Care
CNS
Skin
Head and Neck
Business

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

10 seconds

Playback speed

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

Multiple Myeloma 101: Diagnosis, Prognosis, and Risk

By Dana-Farber Cancer Institute FEATURING Paul Richardson

764 views

July 2, 2024

Comments 0

Hypothetical Patient Case: Hepatocellular Carcinoma with Progression…

Feat. J. Gutierrez, J. Strauss

Hypothetical Patient Case: Hepatocellular Carcinoma and Consideratio…

Feat. J. Gutierrez, J. Strauss

Multiple Myeloma Patient Symposium

Updates on AL Amyloidosis Treatment: What’s New in 2024

Dana-Farber Cancer Institute

G. Bianchi

195 views

Multiple Myeloma 101: Diagnosis, Prognosis, and Risk

Dana-Farber Cancer Institute

P. Richardson

764 views

CAR T-Cells in Multiple Myeloma in 2024

Dana-Farber Cancer Institute

A. Sperling

282 views

Updates in the Management of SMM/MGUS and the Prevention of Progress…

Dana-Farber Cancer Institute

Y. Liu

94 views

Bispecific Antibody Therapy in Multiple Myeloma

Dana-Farber Cancer Institute

S. Midha

76 views

Advances in Multiple Myeloma 2024: From Bench to Bedside

Dana-Farber Cancer Institute

K. Anderson

727 views

Future of Novel Next Generation Therapy in the Management of R/R MM

Dana-Farber Cancer Institute

P. Richardson

232 views

Continued Evolution of Therapy for Patients With Newly Diagnosed MM

Dana-Farber Cancer Institute

C. Mo

146 views